8.4 Generic Drug Substitution, FDA Orange Book & Purple Book Biosimilars

Generic and Interchangeable Biological Product Selection

Mississippi product selection is governed by Miss. Code Ann. §§ 73-21-115 through 73-21-121 and Board Article X. It covers a generic equivalent drug product and an interchangeable biological product. The current statute became effective April 23, 2025 and is scheduled for repeal July 1, 2029 unless changed, so confirm later law.

Lower-cost gate

A pharmacist may select a generic equivalent or interchangeable biological product only when selection results in lower cost to the purchaser, unless the prescriber has prohibited selection. Lower acquisition cost to the pharmacy alone is not the statutory test. Compare what the purchaser actually pays under the transaction.

The pharmacist shall select when the purchaser requests selection, or when the prescriber has not prohibited product selection and selection will lower purchaser cost. Before selection, the pharmacist advises the purchaser of the purchaser’s rights. If the purchaser asks for the product ordered by the prescriber, the pharmacist does not substitute.

This creates three gates: product equivalence/interchangeability, lower purchaser cost, and no controlling prescriber or purchaser refusal.

Prescriber prohibition

For a written prescription, Article X uses the instruction “Dispense as Written.” The current rule should not be replaced by another state’s two-signature-line form or phrases such as “Brand Necessary” or “Medically Necessary” unless the current electronic provision recognizes the brand-necessary specification.

For an electronic prescription, the prescriber specifies that the brand is medically necessary through the system as the rule permits. A patient’s preference and a prescriber prohibition are separate: either can block selection through its own pathway.

Determining equivalence

For small-molecule drugs, use FDA therapeutic-equivalence information in the Orange Book, along with dosage form, strength, route, release characteristics, and product code. An “A” therapeutic-equivalence rating supports substitution within its evaluated context; a “B” code identifies a known or potential bioequivalence issue. Do not infer equivalence from the same active ingredient alone when dosage form or release mechanism differs.

For biologicals, use FDA’s Purple Book information to determine whether the proposed biosimilar has been designated interchangeable with the reference product. Biosimilar status alone is not necessarily the same as interchangeable status for pharmacy-level substitution.

Labeling

When product selection occurs, Mississippi labeling uses G.E. for a generic equivalent or I.B. for an interchangeable biological product as appropriate. A generic label identifies the proprietary name of the product dispensed or the generic name and manufacturer unless the prescriber directs omission of the drug name. An interchangeable biological label includes the FDA-designated nonproprietary name and manufacturer.

The former Mississippi biosimilar communication requirement was removed in the 2025 legislation. Do not teach a universal five-business-day prescriber notice as current law. Other record, payer, clinical, or recall communications still apply.

Liability and judgment

Authorized selection performed according to reasonable and prudent pharmacy practice is not itself evidence of negligence under § 73-21-121. That protection does not excuse selection of a nonequivalent product, failure to honor DAW or purchaser choice, inaccurate labeling, or a clinically inappropriate change.

Exam method

Ask: Is the candidate product therapeutically equivalent or FDA-interchangeable? Does it lower purchaser cost? Did the prescriber prohibit? What does the purchaser choose after being advised? Then apply G.E./I.B. labeling and manufacturer identification.

Selection examples

A brand prescription costs the purchaser $40 and an A-rated generic costs $12. If the prescriber did not prohibit and the purchaser does not insist on brand after advice, selection meets the lower-cost gate. If a coupon makes the brand $5, the $12 generic does not lower purchaser cost for that transaction, so § 73-21-117 does not support selection on the pharmacy’s acquisition savings alone.

For a biosimilar, first verify FDA interchangeability with the exact reference product in the Purple Book. Record and label the nonproprietary name and manufacturer and mark I.B. as Mississippi requires. Do not apply an Orange Book code to a biologic or send a five-day notification solely because an older outline says so. If the prescriber or purchaser blocks selection, document and dispense the ordered product if otherwise available and valid.

If stock is unavailable, the pharmacist may discuss alternatives with the prescriber and purchaser, but shortage does not erase DAW or purchaser choice. A therapeutically different strength, release form, or route requires new prescriber authorization, not substitution.

Product-specific verification

Orange Book evaluation is product-specific. First match active ingredient, strength, dosage form, route, and release design; then read the full therapeutic-equivalence code for the exact application holder and product. An AB1 product is evaluated against the reference product associated with the AB1 group, not automatically against a different reference grouped as AB2. A shared ingredient name therefore does not authorize a change between immediate-release and extended-release products or between different dosage forms.

For a biological product, use the Purple Book to verify the exact reference product and whether FDA has licensed the proposed biosimilar as interchangeable. Then apply Mississippi's lower-purchaser-cost, prescriber-direction, purchaser-choice, and labeling rules. This two-step method prevents a common exam error: treating federal equivalence or interchangeability status as though it alone overrides state conditions for pharmacy-level selection.